Atrioventricular Block Clinical Trial
Official title:
Prospective Analysis of Low-Dose Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart
Heart transplants save the lives of nearly 500 children in heart failure per year. Columbia
is one of the largest pediatric heart transplant centers in the world, averaging 25
transplants per year, and providing ongoing care to nearly 250 children with transplanted
hearts. After transplant, children are at increased risk to develop sudden onset of
abnormally fast heart rates. This research project will study adenosine, a medication that is
routinely used to slow fast heart rates in non-transplanted children (i.e. normal hearts),
and its effects on the transplanted heart. Adenosine is often not used in patients with
transplanted hearts because, based on prior limited research in adult patients, the standard
adult dose may have a longer medication effect, producing a slower heart rate for an
undesirable period of time. However, the current alternatives to adenosine treatment are
either inappropriate for the pediatric age range, or have increased risk of unwanted side
effects. This research project will answer two questions: is adenosine safe to give a child
who has had a heart transplant, and will it be effective in treating the fast heart rate?
All pediatric heart transplant patients undergo regular heart testing, known as a cardiac
catheterization, one or more times per year. Three days before testing, participants will be
asked to stop a regular medication, dipyridamole, because it slows the breakdown of adenosine
in the body, and may increase its effects. (Of note, all patients that are on dipyridamole
are also on aspirin, which gives a second line of heart protection, and will not be stopped.)
After regular cardiac catheterization, all patients will already have intravenous (IV) access
to give medication. Also, this setting allows the opportunity to have a back-up pacing
catheter in the heart, ensuring that there will not be a longer than desired effect from the
medication. Adenosine will be given per a low-dose protocol until either the medication
effect is seen or the maximum dose is reached. There will be no difference in procedure
recovery period time, and patients will resume regular home medications after finishing the
test. As Columbia is one of largest pediatric heart transplant centers in the world, studying
the effects of adenosine at low doses will benefit the investigators population greatly,
either to find a new recommended medication dose, or to provide evidence that this medication
is truly inadvisable for the investigators patients.
The initial study was completed with all 80 patients enrolled and tested. Subsequent testing
is now ongoing on patients in whom dipyridamole was stopped prior to their initial testing
with a repeat study without discontinuing the dipyridamole. We anticipate re-testing about 30
of the 80 patients.
After cardiac catheterization, the study protocol will begin with 12.5µg/kg of adenosine (one
eighth the recommended starting clinical dose), and will double to 25µg/kg, 50µg/kg, 100µg/kg
and finally 200µg/kg (not to surpass the total maximum dose of 12mg). A pacing catheter will
be placed within the right ventricle prior to medication administration. Escalating doses
will stop if ventricular pacing is required due to a ventricular pause greater than 12
seconds or if atrioventricular block is demonstrated with a ventricular pause less than 12
seconds. If there is no prolonged pause requiring pacing and no demonstration of medication
effect the subsequent dose will be given.
Progression to the next dose of the adenosine will depend on both the primary and secondary
study outcomes. If the adenosine dose produces clinically significant bradycardia (> 12
seconds), ventricular pacing will be used to maintain cardiac output, and the dose will be
considered unsafe to use clinically and testing will end for that patient. If the adenosine
dose produces atrioventricular block but with a pause of less than 12 seconds (thus does not
require pacing), the dose will be considered effective and the study will terminate as well.
However, if the adenosine dose does not produce atrioventricular block or require pacing
intervention, the dose will be considered safe but ineffective and the study will progress to
the next higher dose. Before dose progression, the study will pause for additional 30 seconds
to ensure complete adenosine metabolism, as the half-life of adenosine is less than 10
seconds and does not exhibit cumulative effects. The subsequent dose will then be
administered and the ECG observed for clinically significant bradycardia and atrioventricular
block. This will be repeated until clinically significant bradycardia and/or atrioventricular
block is observed, or up to the final 200μg/kg (not to surpass the total maximum of 12mg)
dose.
The same study protocol is being utilized to retest the subset of patients in whom
dipyridamole was discontinued prior to the initial testing to further understand the safety
of administering adenosine to heart transplant patients chronically maintained on
dipyridamole.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Completed |
NCT01019213 -
Acute and Chronic Effect of His-pacing in Consecutive Patients With AV-block
|
Phase 4 | |
Completed |
NCT04884100 -
enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening
|
N/A | |
Recruiting |
NCT05774262 -
Pacemaker Implantation Versus Cardioneuroablation for Functional Atrioventricular Block
|
N/A | |
Terminated |
NCT04093414 -
Left Bundle Area Versus Selective His Bundle Pacing
|
N/A | |
Withdrawn |
NCT00559143 -
Biventricular Alternative Pacing
|
Phase 4 | |
Recruiting |
NCT04730921 -
Impact of Left Bundle Branch Area Pacing vs. Right Ventricular Pacing in Atrioventricular Block (LEAP-Block)
|
N/A | |
Recruiting |
NCT05575557 -
Pulmonary Artery Pressure and Right Heart Evaluation for Patients Requiring Physiological Pacing Treatment
|
N/A | |
Recruiting |
NCT05585411 -
PReventive Effect Of Left Bundle Branch Area Pacing Versus righT vEntricular paCing on All Cause deaTh, Heart Failure Progression, and Ventricular dysSYNChrony in Patients With Substantial Ventricular Pacing (PROTECT-SYNC): Multicenter Prospective Randomized Controlled Trial
|
N/A | |
Completed |
NCT00187278 -
Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization
|
N/A | |
Recruiting |
NCT04595487 -
LVSP vs RVP in Patients With AV Conduction Disorders
|
N/A | |
Completed |
NCT04269733 -
Risk of Pacing-induced Cardiomyopathy
|
||
Recruiting |
NCT03851315 -
Left Bundle Branch Area Pacing in AVB Patients
|
||
Completed |
NCT01922518 -
Impact of Right Ventricular Pacing Determined by Electrocardiography
|
N/A | |
Completed |
NCT02282033 -
Safety and Performance Study of the Moderato System
|
N/A | |
Recruiting |
NCT04624763 -
Protection of Cardiac Function With Left Bundle Branch Pacing in Patients With Atrioventricular Block
|
N/A | |
Completed |
NCT03231826 -
Arrhythmias in Post-Myocardial Infarction Patients
|
||
Not yet recruiting |
NCT04437901 -
COVIDAR - Arrhythmias in COVID-19
|
||
Recruiting |
NCT01717469 -
Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias
|
Phase 4 | |
Completed |
NCT02154750 -
AV Delay Optimization vs. Intrinsic Conduction in Pacemaker Patients With Long PR Intervals
|
N/A |